Glaxo, set back by diabetes drug, sticks to forecast
Article Abstract:
Second-quarter net profit for British pharmaceutical company GlaxoSmithKline PLC rose by 1.4% to reach 1.33 bil pounds sterling, lifted in part from a lower tax rate. Sales, however, dropped by 2.4% to 5.67 bil. The firm is holding to its full-year outlook despite concerns about side effects involving Avandia, its diabetes drug.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Sanofi obesity drug helps sugar levels of diabetics in study
Article Abstract:
Acomplia, an anti-obesity drug being tested by French pharmaceutical company Sanofi-Aventis S.A., is proving beneficial to diabetics. P atients taking the drug showed improved blood-sugar levels and weight loss .
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Despite flat quarter, Glaxo reaffirms '07 growth forecast
Article Abstract:
First-quarter net profit for GlaxoSmithKline PLC rose only slightly to $3.02 bil, with sales declining by 4%. However, prescription drug and vaccine sales are up, supporting expectations of a successful 2007.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Glaxo plans to trim jobs as profit falls. Glaxo expects earnings to fall in 2008
- Abstracts: Alcatel stakes turnaround on more cuts. Alcatel-Lucent enters new area with laptop-security product
- Abstracts: Taxing incentives: how to reduce taxable benefits when doling out rewards and perks
- Abstracts: The web to go. In pursuit of Purple Cows